Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 4 non-adjuvanted pandemic influenza candidate vaccines
4 adjuvanted pandemic influenza candidate vaccines · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| 4 adjuvanted pandemic influenza candidate vaccines | BIOLOGICAL | - |
| 4 non-adjuvanted pandemic influenza candidate vaccines | BIOLOGICAL | - |
Inclusion criteria: * A male or female between, and including, 18 and 60 years of age at the time of the first vaccination. * Healthy subjects as established by medical history and clinical examination before entering into the study. * If the subject is female, she must be of non-childbearing poten...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
It is a group of four adjuvanted pandemic influenza vaccine candidates developed by GSK plc. These vaccine candidates are designed for use against pandemic influenza and were evaluated together in a Phase 1 clinical study in adults aged 18 to 60 years. The program is in early clinical development.
The four adjuvanted pandemic influenza candidate vaccines are intended for immunization against pandemic influenza. They were studied in healthy adult volunteers aged 18 to 60 years to assess safety and immune response. The candidates target influenza, an infectious disease, and remain investigational.
GSK plc, which trades under the ticker GSK, is the developer of the four adjuvanted pandemic influenza candidate vaccines. GSK sponsored the Phase 1 clinical trial evaluating these candidates in Belgium. The company is the sole developer named for this vaccine program.
The four adjuvanted pandemic influenza candidate vaccines are in Phase 1 clinical development. The program has completed one Phase 1 trial with 400 participants. These vaccine candidates are investigational and have not been approved for use.
The four adjuvanted pandemic influenza candidate vaccines were evaluated in one completed Phase 1 trial, NCT00309634, titled a study to evaluate the safety and immunogenicity of a pandemic influenza vaccine in adults aged between 18 and 60 years. The trial enrolled 400 participants in Belgium and was randomized but uncontrolled.